Share on Twitter Share by Email Share Back to top The U.S. Food and Drug Administration (FDA) recently announced a new Commissioner’s National Priority Voucher (CNPV) program, via a press release accompanied by a list of...more
7/15/2025
/ Clinical Trials ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
Healthcare ,
Patent Litigation ,
Pharmaceutical Industry ,
Prescription Drugs ,
Public Health ,
Regulatory Reform ,
Regulatory Requirements ,
Vouchers
On the heels of a year beset by turmoil and the myriad challenges caused by the global pandemic, the cannabis industry nevertheless entered 2021 poised for significant growth amid a landscape teeming with opportunity. Public...more
2/26/2021
/ Banking Sector ,
Cannabidiol (CBD) oil ,
Cannabis-Related Businesses (CRBs) ,
Capital Markets ,
Controlled Substances Act ,
Department of Justice (DOJ) ,
Enforcement Actions ,
Environmental Policies ,
Financial Institutions ,
Food and Drug Administration (FDA) ,
Insolvency ,
Insurance Industry ,
Internal Revenue Code (IRC) ,
Marijuana Related Businesses ,
Patent Litigation ,
Patents ,
Restructuring ,
Securities and Exchange Commission (SEC) ,
Trademarks ,
USPTO
The Food and Drug Administration’s (FDAs) Arthritis Advisory Committee gave a thumbs up to a biosimilar copy of Johnson & Johnson’s Remicade product, an inflammation blocker used in the treatment of rheumatoid arthritis, on...more
2/12/2016
/ Advisory Committee ,
Amgen ,
Biologics ,
Biosimilars ,
FDA Approval ,
Food and Drug Administration (FDA) ,
Johnson & Johnson ,
Patent Litigation ,
Pharmaceutical Industry ,
Prescription Drugs ,
Sandoz